Skip to content

Comparison of Platelet Rich in growth factor and Hyaluronic acid in patients with knee osteoarthritis

The effect of intra articular injection of plasma rich in growth factors(PRGF) in comparison with hyaluronic acid(HA) on pain and function of patients with knee osteoarthritis, single blind clinical trial

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT2016071513442N11
Enrollment
60
Registered
2016-11-03
Start date
2015-11-22
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Knee osteoarthritis (Gonarthrosis). Gonarthrosis [arthrosis of knee]

Interventions

Intervention 1: Intervention group 1: platelet rich in growth factor, knee intraarticular injection, 4 to 6 milliliter, 2 times, 4 weeks interval. Intervention 2: Intervention group 2: Hyaluronic acid
Treatment - Drugs
Intervention group 1: platelet rich in growth factor, knee intraarticular injection, 4 to 6 milliliter, 2 times, 4 weeks interval

Sponsors

Physical Medicine and Rehabilitation Department of Shahid Beheshti University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 70 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: arthralgia since the past 3 months; radiologic evidence of articular damage (grade 2,3 of Kellgren-Lawrence scale) based on knee OA criteria of ACR. Exclusion criteria: systemic diseases such as diabetes mellitus and collagen vascular disorders; history or presence of cancer or malignant disorders; any infection and active wound of the knee; presence of immunosuppressive, autoimmune and platelet disorders; treatment with anticoagulant and anti-platelet medications 10 days before injection; use of NSAIDs 2 days before injection; history of knee articular injections of corticosteroids 3 weeks or use of systemic corticosteroids 2 weeks before PRP injections; hemoglobin measures of less than 12 g/dl and platelet counts of less than 150,000 per micro liter; recent history of severe trauma to the knee; age less than 45 or over 75 year; history of vasovagal shock; pregnancy; breastfeeding; genu valgum/varum greater than 20 degrees.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Knee pain. Timepoint: before intervention, 2 months & 6 months after intervention. Method of measurement: WOMAC questionnaire.;Function. Timepoint: before intervention, 2 months & 6 months after intervention. Method of measurement: WOMAC questionnaire.;The maximum distance of walking. Timepoint: before intervention, 2 months & 6 months after intervention. Method of measurement: Lequesne Index.;Activity of daily living. Timepoint: before intervention, 2 months & 6 months after intervention. Method of measurement: Lequesne Index.;Joint Stiffness. Timepoint: before intervention, 2 months & 6 months after intervention. Method of measurement: WOMAC questionnaire.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAzadeh Gharooei Ahangar

Shahid Beheshti Univeraity of Medical Sciences

azadeh.gh67@gmail.com+98 21 2273 1112

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026